Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial

Area of Science:

• Gerontology
• Endocrinology
• Men's Health

Background:

• Testicular function decline is common in aging men, but its impact on physical and cognitive aging is understudied.
• Hypogonadism, defined as low bioavailable testosterone, affects a significant portion of the older male population.
• Limited data exists on the long-term effects of testosterone supplementation in hypogonadal older men.

Purpose of the Study:

• To investigate the year-long effects of testosterone administration on physical and cognitive function in hypogonadal older men.
• To assess changes in grip strength, hemoglobin, prostate-specific antigen, leptin, and memory.
• To evaluate the safety and efficacy of testosterone supplementation in this demographic.

Main Methods:

• A 12-month randomized, placebo-controlled trial involving hypogonadal men (bioavailable testosterone <60 ng/dL).
• Participants received either 200 mg testosterone cypionate injections biweekly or a placebo.
• Outcomes included grip strength, hemoglobin, prostate-specific antigen, leptin levels, and cognitive tests.

Main Results:

• Testosterone significantly improved bilateral grip strength (P < 0.05) and increased hemoglobin levels (P < 0.001).
• Testosterone treatment led to greater decreases in leptin levels compared to placebo (P < 0.02).
• No significant changes were observed in prostate-specific antigen or memory function; however, higher withdrawal rates occurred in the testosterone group due to elevated hematocrit.

Conclusions:

• Testosterone supplementation in older hypogonadal men enhances physical strength, increases hemoglobin, and reduces leptin.
• Testosterone may play a role in managing frailty in hypogonadal males.
• Close monitoring of older men undergoing testosterone therapy is crucial due to potential adverse effects, such as elevated hematocrit.